MiamiHerald.com: Press Releases - Biotechnology

Micross Components Hosts Stop on "Drive for Innovation" Tour

Thu, 09 Feb 2012 09:56 EST

/PRNewswire/ -- Micross Components, a leading global provider of distributed and specialty electronic solutions, is pleased to announce its participation in the "Drive for Innovation" tour, sponsored by Avnet Express and UBM Electronics. Included as a "pit stop" during the tour's recent swing through Central Florida, Micross was selected because of its role in powering innovation by companies driving technological advancements across defense, space, medical and other high-reliability industries.

Divine Skin Q4 Tops $3 million; 2011 Revenue Reaches $9.6 million, Up 78% Over 2010

Thu, 09 Feb 2012 08:11 EST

/PRNewswire/ -- Today Divine Skin (OTC Bulletin Board: DSKX) released preliminary revenue figures for the fourth quarter, $3.1 million, up 63 percent over the same quarter of 2010 and up 48 percent over the third quarter of 2011. For the year 2011, revenue totaled $9.6 million, up 78 percent over 2010.

FDA's Grace McNally to Appear at ISPE Facilities Conference

Wed, 08 Feb 2012 10:15 EST

Event to explore lessons learned from FDA 483s in tracks focused on Biotech, Oral Solid Dosage Processing and Containment, and Process Validation

RTI Biologics Highlights Biologic Implants, Public Education Website at 2012 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting

Wed, 08 Feb 2012 08:15 EST

RTI Biologics Inc. (RTI) (Nasdaq: RTIX), a leading provider of orthopedic and other biologic implants, is highlighting two new allografts and introducing a public education website at the American Academy of Orthopaedic Surgeons (AAOS) annual meeting in San Francisco this week. BioAdapt™ DBM, a sterile, room temperature DBM implant that provides a contoured fit to bony defects; Fresh-stored Osteochondral Humeral Head, an allograft that enables surgeons to resurface osteochondral defects in a single procedure; and AllograftInfo.com, an informational website to educate patients and the general public about allograft tissue, will be showcased at the RTI Biologics exhibit at booth 4137 (Hall E) during the AAOS meeting at the Moscone Center.

Big VC Biotech Spending on the Rise for 2012

Wed, 08 Feb 2012 05:10 EST

As Rainbow BioSciences, the biotech division of Rainbow Coral Corp. (OTCBB: RBCC), continues to vet investment banks to assist with its capital raise, investors remain optimistic on the returns that new biotech firms can bring. A recent report indicates that venture capital investments in biotech increased by 22 percent to $4.7 billion last year.

Hino Trucks Honored at National Biodiesel Conference

Tue, 07 Feb 2012 14:15 EST

/PRNewswire/ -- During a ceremony today at the National Biodiesel Conference in Orlando, Hino Trucks was recognized by the National Biodiesel Board with the 2012 "Eye on Biodiesel Impact Award."

Amyris to Hold Conference Calls and Participate in Investor Conferences

Mon, 06 Feb 2012 16:10 EST

Amyris, Inc. (NASDAQ: AMRS) announced today that it will provide an investor update regarding its progress and near term goals on a conference call commencing after market close on Thursday, February 9, 2012, starting at 5:00 p.m. Eastern Standard Time. To participate via live webcast, please visit: http://investors.amyris.com.

BioStorage Technologies to Host Global Sample Management Workshop at Partnerships in Clinical Trials

Mon, 06 Feb 2012 14:05 EST

/PRNewswire/ -- BioStorage Technologies, a global provider of comprehensive sample management solutions, biomaterial storage and cold chain logistics for the bioscience industry, will host its Global Sample Management Benchmarking Workshop at Partnerships in Clinical Trials on Tuesday, March 6, 2012 at the Marriott World Center in Orlando, Florida.

BiovaxID® Personalized Lymphoma Vaccine is Featured in Article Published in HemOnc Today

Mon, 06 Feb 2012 09:30 EST

Biovest International, Inc. (OTCQB: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: ABPI), today announced that an article was published in HemOnc Today, reporting on the promise of Biovest’s BiovaxID® personalized cancer vaccine for the treatment of non-Hodgkin’s lymphoma, an incurable form of blood cancer.

RBCC Negotiates Funding Terms With n3D

Mon, 06 Feb 2012 05:10 EST

Rainbow Biosciences, the biotech division of Rainbow Coral Corp. (OTCBB:RBCC), announced today that it’s on the cusp of a major breakthrough in its business relationship with n3D Biosciences.

RBCC: Biotech Industry on Major Upswing in 2012

Fri, 03 Feb 2012 05:07 EST

All signs point to emerging biotech company Rainbow Coral Corp. (OTCBB:RBCC) finding its feet in biotechnology at exactly the right time: The biotech industry is off to a great start in the early stages of 2012.

Insero Health Closes Initial Round of Financing and Signs Exclusive Licenses With Harvard and Yale

Thu, 02 Feb 2012 07:37 EST

OneMedPlace Initiates Research Coverage on Biovest and BiovaxID® Personalized Lymphoma Vaccine

Wed, 01 Feb 2012 09:53 EST

Biovest International, Inc. (OTCQB: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: ABPI), today announced that OneMedPlace, a biotechnology-focused research and media organization engaged by Biovest, has initiated research coverage on Biovest. The new report, issued this week by Dr. Malini Chatterjee, Ph.D., discusses the anticipated regulatory pathway and market opportunity for BiovaxID®, Biovest’s personalized cancer vaccine for the treatment of certain B-cell subtypes of non-Hodgkin’s lymphoma (NHL).

BioRestorative Therapies Signs License Agreement for Stem Cell Disc/Spine Procedure

Tue, 31 Jan 2012 09:08 EST

/PRNewswire/ -- BioRestorative Therapies, Inc. (OTCQB: BRTX) ("BRT") today announced that it has entered into a License Agreement with Regenerative Sciences, LLC ("RS") with respect to certain stem cell-related technology and clinical treatment procedures developed by RS. The treatment is an advanced stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, or numbness and tingling in the legs or feet as a result of bulging and herniated discs.

New Clinical Data for Symphony Presented in Late Breaking Clinical Trials Session at the Society of Thoracic Surgeons 2012 Annual Meeting

Tue, 31 Jan 2012 08:13 EST

Abiomed Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that the initial clinical data from the safety study for Symphony™ was presented by Renzo Cecere, M.D., FRCSC, FACS, Associate Professor of Surgery at McGill University, during the late-breaking clinical trials session at the Society of Thoracic Surgeons (STS) 2012 Annual Meeting in Fort Lauderdale, Florida.

Get Your Sexy Back and Keep It - Real Life Mojo Therapy for the Modern Woman

Mon, 30 Jan 2012 18:11 EST

/PRNewswire/ -- For women over forty who have lost their mojo and just about everything that goes with it, Dr. Jennifer Landa's new book The Sex Drive Solution for Women, Dr. Jen's Power Plan to Fire Up Your Libido will inspire women to take charge of their bodies and minds to create permanent, fulfilling change. And it is on sale now on Amazon.com.

Newly-trademarked rED Cap™ Clinical Trials Software Offers Affordable Electronic Data Capture

Mon, 30 Jan 2012 14:51 EST

/PRNewswire/ -- rED Cap™, the proprietary, web-based clinical trial data management software developed by BioStat International, Inc. (BSI), recently received trademark status.

RBCC Explores New Cures for Cancer, Brain Injuries & Headaches

Mon, 30 Jan 2012 05:06 EST

Cutting-edge stem cell research is producing new breakthroughs that could potentially revolutionize the treatment of currently incurable diseases from cancer to brain injuries to headaches. Rainbow Coral Corp. (OTCBB:RBCC), an emerging biotechnology company, is hard at work identifying and targeting promising new stem-cell treatments for commercialization.

Watson Reaches Settlement with Mallinckrodt Over Exalgo(R)

Thu, 26 Jan 2012 16:09 EST

PARSIPPANY, N.J., Jan. 26, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc.- Florida has reached a settlement with Mallinckrodt Inc. on outstanding patent litigation related to Watson's generic versions of Mallinckrodt's Exalgo® (Hydromorphone Hydrochloride Extended-Release ) tablets. Mallinckrodt filed its lawsuit on December 10, 2010 in the United States District Court for the District of New Jersey following Watson's filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its product in the 8 mg, 12 mg, and 16 mg dosage strengths.Under terms of the settlement agreement, Mallinckrodt has granted Watson a royalty-free license to U.S. patents relating to Exalgo®. Watson will have the right to launch its bioequivalent products on November 15, 2013. Other details of the settlement were not disclosed.

RBCC Seeks Out the Next Big Bioscience Breakthrough

Wed, 25 Jan 2012 10:20 EST

Rainbow BioSciences, a division of Rainbow Coral Corp. (OTCBB: RBCC), is staying connected in the center of advanced bio-research in Houston.